Distribution of serum adiponectin isoforms in pediatric patients with steroid-sensitive nephrotic syndrome.
Adiponectin
Adiponectin isoform
Children
High-molecular-weight
Nephrotic syndrome
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
31
12
2020
accepted:
25
05
2021
pubmed:
2
6
2021
medline:
12
1
2022
entrez:
1
6
2021
Statut:
ppublish
Résumé
Serum adiponectin circulates in three multimeric isoforms: high-molecular-weight (HMW), middle-molecular-weight (MMW), and low-molecular-weight (LMW) isoforms. Potential change in the circulating adiponectin levels in patients with nephrotic syndrome (NS) remain unknown. This study aimed to assess the levels of total adiponectin and the distribution of its isoforms in pediatric patients with NS. We sequentially measured total adiponectin and each adiponectin isoform levels at the onset of NS, initial remission, and during the remission period of the disease in 31 NS patients. We also calculated the ratios of HMW (%HMW), MMW (%MMW), and LMW (%LMW) to total adiponectin incuding 51 control subjects. The median of total serum adiponectin levels in patients were 36.7, 36.7, and 20.2 μg/mL at the onset, at initial remission, and during the remission period of NS, respectively. These values were significantly higher than those in control subjects. The median values of %HMW, %MMW, and %LMW values were 56.9/27.0/14.1 at the onset, 62.0/21.8/13.4 at the initial remission, and 58.1/21.7/17.5 at during the remission period of NS, respectively. Compared with control subjects, %HMW at initial remission and %MMW at the onset were high, and the %LMW values at the onset and at initial remission were low. In patients with NS, total serum adiponectin levels increase at the onset of the disease, and the ratio of adiponectin isoforms changes during the course of the disease. Further studies are needed to delineate the mechanisms between proteinuria and adiponectin isoforms change.
Sections du résumé
BACKGROUND
BACKGROUND
Serum adiponectin circulates in three multimeric isoforms: high-molecular-weight (HMW), middle-molecular-weight (MMW), and low-molecular-weight (LMW) isoforms. Potential change in the circulating adiponectin levels in patients with nephrotic syndrome (NS) remain unknown. This study aimed to assess the levels of total adiponectin and the distribution of its isoforms in pediatric patients with NS.
METHODS
METHODS
We sequentially measured total adiponectin and each adiponectin isoform levels at the onset of NS, initial remission, and during the remission period of the disease in 31 NS patients. We also calculated the ratios of HMW (%HMW), MMW (%MMW), and LMW (%LMW) to total adiponectin incuding 51 control subjects.
RESULTS
RESULTS
The median of total serum adiponectin levels in patients were 36.7, 36.7, and 20.2 μg/mL at the onset, at initial remission, and during the remission period of NS, respectively. These values were significantly higher than those in control subjects. The median values of %HMW, %MMW, and %LMW values were 56.9/27.0/14.1 at the onset, 62.0/21.8/13.4 at the initial remission, and 58.1/21.7/17.5 at during the remission period of NS, respectively. Compared with control subjects, %HMW at initial remission and %MMW at the onset were high, and the %LMW values at the onset and at initial remission were low.
CONCLUSIONS
CONCLUSIONS
In patients with NS, total serum adiponectin levels increase at the onset of the disease, and the ratio of adiponectin isoforms changes during the course of the disease. Further studies are needed to delineate the mechanisms between proteinuria and adiponectin isoforms change.
Identifiants
pubmed: 34061287
doi: 10.1007/s10157-021-02085-w
pii: 10.1007/s10157-021-02085-w
pmc: PMC8357647
doi:
Substances chimiques
Adiponectin
0
Anti-Inflammatory Agents
0
Protein Isoforms
0
Prednisolone
9PHQ9Y1OLM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1027-1034Subventions
Organisme : Japan Society for the Promotion of Science (JP)
ID : JP17K10154
Informations de copyright
© 2021. The Author(s).
Références
Biochimie. 2012 Oct;94(10):2150-6
pubmed: 22980197
Diabetes Care. 2006 Jun;29(6):1357-62
pubmed: 16732021
Cardiovasc Hematol Disord Drug Targets. 2008 Mar;8(1):7-46
pubmed: 18336252
J Assoc Physicians India. 2010 Jan;58:30, 35-40
pubmed: 20649096
J Am Soc Nephrol. 2002 Jan;13(1):134-141
pubmed: 11752030
Cardiovasc Ther. 2009 Spring;27(1):59-75
pubmed: 19207481
Vitam Horm. 2012;90:163-86
pubmed: 23017716
J Biol Chem. 2004 Mar 26;279(13):12152-62
pubmed: 14699128
Cardiovasc Diabetol. 2013 Sep 28;12:137
pubmed: 24073643
Nephrol Dial Transplant. 2006 Dec;21(12):3475-80
pubmed: 16951422
Clin Chim Acta. 2006 Oct;372(1-2):47-53
pubmed: 16697359
J Clin Endocrinol Metab. 2002 Oct;87(10):4652-6
pubmed: 12364452
J Endocrinol. 2017 Aug;234(2):101-114
pubmed: 28705835
Obesity (Silver Spring). 2014 Feb;22(2):401-7
pubmed: 23818415
Kidney Int. 2004 Jan;65(1):274-81
pubmed: 14675060
Eur J Endocrinol. 2004 Mar;150(3):339-44
pubmed: 15012619
Kidney Int Rep. 2019 Sep 19;5(1):66-80
pubmed: 31922062
Biomed Res. 2016;37(3):215-20
pubmed: 27356609
Am J Cardiol. 2006 Dec 15;98(12):1603-8
pubmed: 17145218
Clin Exp Nephrol. 2015 Feb;19(1):6-33
pubmed: 25653046
Biochem J. 2008 Feb 1;409(3):623-33
pubmed: 18177270
Diabetes. 2009 Sep;58(9):2093-9
pubmed: 19509019
Front Endocrinol (Lausanne). 2011 Nov 08;2:62
pubmed: 22649379
Child Obes. 2016 Dec;12(6):440-445
pubmed: 27584617
Cardiovasc Diabetol. 2014 Jun 23;13:103
pubmed: 24957699
J Neurol Sci. 2017 Oct 15;381:169-175
pubmed: 28991674
Kidney Int. 2009 Jul;76(2):145-8
pubmed: 19404275
Nephrology (Carlton). 2008 Oct;13(5):405-10
pubmed: 18522702
J Clin Endocrinol Metab. 2006 Dec;91(12):5113-6
pubmed: 16984991
Pediatr Nephrol. 2005 Apr;20(4):474-7
pubmed: 15690190
Pediatr Nephrol. 2015 Nov;30(11):1977-85
pubmed: 26115618
Eur J Endocrinol. 2010 Mar;162(3):551-7
pubmed: 20019129
Acta Paediatr. 2006 Oct;95(10):1312-4
pubmed: 16982510
J Clin Endocrinol Metab. 2001 May;86(5):1930-5
pubmed: 11344187
J Clin Invest. 2008 May;118(5):1645-56
pubmed: 18431508
Kidney Int Suppl. 2003 May;(84):S98-102
pubmed: 12694320